Richard Y. Cheng
Since late 2013, Richard has represented a broad range of cannabis related businesses, including investors, licensed medical cannabis providers, cannabinoid based bio-pharmaceutical companies, cannabis consulting companies, processors, online marketing companies, brokers, cultivators, seed developers, dispensaries, labs, ancillary retailers and a broad spectrum of hemp-based businesses. He advises clients on regulatory and transactional matters in the cannabis industry. From 2015-2019, Richard served as the outside general counsel for the Texas Cannabis Industry Association (TCIA). In 2019, he was invited by the National Cannabis Bar Association to participate in its FDA Coalition, allowing him to co-author the cannabis primer for the FDA in preparation for the FDA public hearing to address CBD related issues. Richard played a primary role in launching the global cannabis practice group and the US based hemp working group at DLA Piper, a global full service law firm with over 5000 attorneys. Richard will be teaching Cannabis Law at the University of North Texas (UNT) School of Law as an adjunct professor starting in August 2020.
In addition, Richard has a health care practice focused on corporate transactions, regulatory and compliance matters. He primary represents a variety of healthcare providers (e.g. physician groups, nursing facilities, rehabilitation providers, etc.), venture capitalists and private equity groups. He is board certified in healthcare compliance. Richard has considerable experience representing clients involving Stark Law, Anti-Kickback Statute, FCA, EKRA, HIPAA, HITECH Act, Civil Monetary Penalties (CMPs), state based healthcare regulations, Medicare-related transactions (e.g. change of ownership) licensure surveys, formation of MSOs and DSOs, managed care organization (MCO) payment matters, Medicaid contracting and Medicare appeals before administrative law judges.